(Translated by https://www.hiragana.jp/)
Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis of Production and Immunogenicity - Dipòsit Digital de Documents de la UAB
@article{ddd.uab.cat:281324,
      author = {Ortiz, Raquel and Barajas Vélez, Ana and Pons-Grífols, Anna
               and Trinité, Benjamin and Tarrés-Freixas, Ferran and Rovirosa,
               Carla and Urrea, Víctor and Barreiro Vázquez, Antonio and
               Gonzalez-Tendero, Anna and Cardona, Maria and Ferrer, Laura and
               Clotet Sala, Bonaventura and Carrillo, Jorge and Aguilar-
               Gurrieri, Carmen and Blanco, Julià},
       title = {Exploring FeLV-Gag-Based VLPs as a New Vaccine Platform-Analysis
               of Production and Immunogenicity},
     journal = {International journal of molecular sciences},
        year = {2023},
      volume = {24},
       month = {5},
    abstract = {Feline leukemia virus (FeLV) is one of the most prevalent
               infectious diseases in domestic cats. Although different
               commercial vaccines are available, none of them provides full
               protection. Thus, efforts to design a more efficient vaccine are
               needed. Our group has successfully engineered HIV-1 Gag-based
               VLPs that induce a potent and functional immune response against
               the HIV-1 transmembrane protein gp41. Here, we propose to use
               this concept to generate FeLV-Gag-based VLPs as a novel vaccine
               strategy against this retrovirus. By analogy to our HIV-1
               platform, a fragment of the FeLV transmembrane p15E protein was
               exposed on FeLV-Gag-based VLPs. After optimization of Gag
               sequences, the immunogenicity of the selected candidates was
               evaluated in C57BL/6 and BALB/c mice, showing strong cellular and
               humoral responses to Gag but failing to generate anti-p15E
               antibodies. Altogether, this study not only tests the versatility
               of the enveloped VLP-based vaccine platform but also sheds light
               on FeLV vaccine research.},
         doi = {10.3390/ijms24109025},
         url = {https://ddd.uab.cat/record/281324},
}